Abstract
Background Good information on the harm of a drug is vital to inform risk-benefit decisions and undertake robust cost effectiveness analysis. Clinical trials reported in peerreviewed articles are not useful for this purpose [1,2]. Regulators require pharmaceutical companies to produce product information documents (Europe:SmPC, US:USPI). These documents contain comprehensive and valuable publicly available information on the known harm of a drug and have the potential to inform important risk-benefit decisions. We reviewed the usefulness of the data presented and compared the harm profile reported in documents for brand drugs marketed in Europe and the US.
Highlights
Good information on the harm of a drug is vital to inform risk-benefit decisions and undertake robust cost effectiveness analysis
Inclusion: Antidepressants/antiepileptic brand drugs evaluated in randomised trials of neuropathic pain and marketed in the US and Europe
It is expected that the harm profile in the product information for the same drug should agree
Summary
Usability and consistency of harm information in drug product descriptions: a matched comparison of data between the United States (US) and Europe. From The 4th Meeting of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative Rome, Italy. From The 4th Meeting of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative Rome, Italy. 19-20 November 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
